DK0843961T3 - Kimærisk mus og fremgangsmåde til at producere samme - Google Patents

Kimærisk mus og fremgangsmåde til at producere samme

Info

Publication number
DK0843961T3
DK0843961T3 DK96928694T DK96928694T DK0843961T3 DK 0843961 T3 DK0843961 T3 DK 0843961T3 DK 96928694 T DK96928694 T DK 96928694T DK 96928694 T DK96928694 T DK 96928694T DK 0843961 T3 DK0843961 T3 DK 0843961T3
Authority
DK
Denmark
Prior art keywords
same
fragment
producing same
chimeric mouse
producing
Prior art date
Application number
DK96928694T
Other languages
Danish (da)
English (en)
Inventor
Kazunori Hanaoka
Mitsuo Oshimura
Isao Ishida
Hitoshi Yoshida
Kazuma Tomizuka
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of DK0843961T3 publication Critical patent/DK0843961T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK96928694T 1995-08-29 1996-08-29 Kimærisk mus og fremgangsmåde til at producere samme DK0843961T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP24234095 1995-08-29
JP2794096 1996-02-15
PCT/JP1996/002427 WO1997007671A1 (fr) 1995-08-29 1996-08-29 Animal chimerique et procede de constitution

Publications (1)

Publication Number Publication Date
DK0843961T3 true DK0843961T3 (da) 2007-05-21

Family

ID=26365944

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96928694T DK0843961T3 (da) 1995-08-29 1996-08-29 Kimærisk mus og fremgangsmåde til at producere samme

Country Status (12)

Country Link
EP (3) EP0773288A3 (de)
JP (1) JP4318736B2 (de)
KR (1) KR100308764B1 (de)
CN (2) CN101333516A (de)
AT (1) ATE352613T1 (de)
AU (1) AU718138B2 (de)
CA (1) CA2230759C (de)
DE (1) DE69636868T2 (de)
DK (1) DK0843961T3 (de)
HK (1) HK1008472A1 (de)
TW (1) TW448032B (de)
WO (1) WO1997007671A1 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908127D0 (en) * 1989-04-11 1989-05-24 Shaw Francis & Co Ltd Mixer and a method of a mixer control
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
ATE332077T1 (de) * 1997-02-28 2006-07-15 Kirin Brewery Transgene mäuse die ein menschliche antikörper exprimieren
AU7057398A (en) * 1997-04-11 1998-11-11 Imperial College Of Science, Technology And Medicine Chromosome transfer (xmmct) to es cells, induced during the exposure of microcells to radiation
TWI255853B (en) 1998-08-21 2006-06-01 Kirin Brewery Method for modifying chromosomes
JP4689781B2 (ja) * 1998-09-03 2011-05-25 独立行政法人科学技術振興機構 アミノ酸輸送蛋白及びその遺伝子
WO2000072881A1 (en) 1999-06-01 2000-12-07 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
WO2001011951A1 (en) * 1999-08-13 2001-02-22 Kirin Beer Kabushiki Kaisha Mouse having human cytochrome p450 transferred therein
DE60033530T2 (de) * 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US7414170B2 (en) 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7820878B2 (en) 1999-11-19 2010-10-26 Kyowa Hakko Kirin Co., Ltd. Production of ungulates, preferably bovines that produce human immunoglobulins
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
CA2403140A1 (en) * 2000-04-07 2001-10-18 Peter Marynen Novel chromosomal vectors and uses thereof
KR100882030B1 (ko) 2000-11-17 2009-02-09 교와 핫꼬 기린 가부시키가이샤 클로닝된 트랜스제닉 유제류에서 이종 (사람)면역글로블린의 발현
AU3942202A (en) 2000-11-30 2002-06-11 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
ES2389251T3 (es) * 2000-12-19 2012-10-24 Altor Bioscience Corporation Animales transgénicos que comprenden un sistema inmunitario humanizado
US7358054B2 (en) 2001-04-13 2008-04-15 Biogen Idec Ma Inc. Antibodies to VLA-1
JP2002316944A (ja) * 2001-04-17 2002-10-31 Chemo Sero Therapeut Res Inst ヒトポリクローナル抗体組成物
EP1632571B1 (de) * 2001-05-11 2012-11-28 Kyowa Hakko Kirin Co., Ltd. Künstliches menschliches Chromosom mit dem Gen für die menschliche Antikörper Lambda leichte Kette und ein nicht-menschliches Tier enthaltend ein künstliches menschliches Chromosom fähig zur genetischen Transmission
WO2003041495A1 (fr) * 2001-11-15 2003-05-22 Kirin Beer Kabushiki Kaisha Animal chimerique
US7303896B2 (en) 2002-02-25 2007-12-04 Genentech, Inc. Nucleic acid encoding novel type-1 cytokine receptor GLM-R
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
WO2003086459A1 (en) 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
CN1668187A (zh) * 2002-05-17 2005-09-14 赫马技术有限公司 能够产生人抗体的转基因有蹄动物
EP2243493A1 (de) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotenzierende Zusammensetzung
ATE549033T1 (de) 2002-09-06 2012-03-15 Amgen Inc Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
US7429690B2 (en) 2002-11-08 2008-09-30 Kirin Holdings Kabushiki Kaisha Transgenic bovines having reduced prion protein production
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
NZ544486A (en) 2003-06-13 2009-04-30 Biogen Idec Inc Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
CN102675462A (zh) 2003-06-27 2012-09-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
EP1659918B1 (de) 2003-08-08 2009-01-14 Amgen Fremont Inc. Antikörper gegen parath-hormon (pth) und ihre verwendungen
EP1533617A1 (de) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
ES2362667T3 (es) 2004-01-09 2011-07-11 Pfizer Inc. ANTICUERPOS FRENTE A MAdCAM.
CA2564989C (en) 2004-03-19 2014-05-27 Amgen, Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
US7420099B2 (en) 2004-04-22 2008-09-02 Kirin Holdings Kabushiki Kaisha Transgenic animals and uses thereof
EP1791563A4 (de) 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154-antikörper
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
AU2005299413A1 (en) 2004-10-22 2006-05-04 Revivicor, Inc. Ungulates with genetically modified immune systems
EP1824886B1 (de) 2004-11-17 2010-12-22 Amgen Inc. Vollständige humane monoklonale antikörper gegen il-13
TW200635946A (en) 2004-12-20 2006-10-16 Abgenix Inc Binding proteins specific for human matriptase
KR101017301B1 (ko) 2004-12-21 2011-02-28 메드임뮨 리미티드 앤지오포이에틴-2에 대한 항체 및 그의 용도
ES2395953T3 (es) 2005-01-26 2013-02-18 Amgen Fremont Inc. Anticuerpos frente a interleucina-1 beta
SI2161336T1 (sl) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
KR20080039999A (ko) 2005-08-18 2008-05-07 젠맵 에이/에스 Ｃｄ４ 결합 펩티드 및 방사선을 이용한 치료
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
EP1954311A4 (de) 2005-12-07 2009-12-23 Medarex Inc Ctla-4-antikörper-dosierungseskalationstherapien
ATE552853T1 (de) 2005-12-13 2012-04-15 Medimmune Ltd Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
HUE039353T2 (hu) 2005-12-13 2018-12-28 Lilly Co Eli Anti-IL-17 ellenanyagok
EP3168234A1 (de) 2005-12-15 2017-05-17 Medimmune Limited Kombination eines angiopoetin-2-antagonisten und eines vegf-a, kdr- und/oder fltl-antagonisten zur behandlung von krebs
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
RU2429246C2 (ru) * 2006-02-28 2011-09-20 Онкотерапи Сайенс, Инк. СПОСОБЫ РАЗРУШЕНИЯ КЛЕТОК С ИСПОЛЬЗОВАНИЕМ ЭФФЕКТОРНЫХ ФУНКЦИЙ АНТИ-EphA4 АНТИТЕЛ
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
TW200817512A (en) 2006-07-07 2008-04-16 Kirin Pharma Kk Human artificial chromosome (hac) vector, and human cell pharmaceutical comprising human artificial chromosome (hac) vector
EP2046374A4 (de) 2006-07-10 2010-05-05 Biogen Idec Inc Zusammensetzungen und verfahren zur wachstumshemmung von smad4-defizienten tumoren
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
RU2009107277A (ru) 2006-08-03 2010-09-10 Астразенека Аб (Se) АНТИТЕЛА, НАЦЕЛЕННЫЕ НА αVβ6, И ИХ ПРИМЕНЕНИЕ
US8007797B2 (en) 2006-09-28 2011-08-30 Merck Serono S.A. Junctional adhesion molecule-C (JAM-C) binding compounds and methods of their use
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CA2680549A1 (en) 2007-03-12 2008-09-18 Alan D. D'andrea Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
CA2681530C (en) 2007-03-22 2017-03-28 Biogen Idec Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154
EP2006304A1 (de) * 2007-06-22 2008-12-24 Stiftung Für Diagnostische Forschung Monokloner Antikörper gegen HPA-5b
JP5624884B2 (ja) * 2007-08-02 2014-11-12 ノビミューンエスアー 抗ｒａｎｔｅｓ抗体およびその使用の方法
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
EP4248976A3 (de) 2007-08-23 2024-04-10 Amgen Inc. Antigen zur bindung von proteinen an proprotein-konvertase-subtilisin/kexin vom typ 9 (pcsk9)
SG187477A1 (en) 2007-09-26 2013-02-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
KR101554848B1 (ko) * 2007-10-01 2015-09-21 브리스톨-마이어스 스큅 컴퍼니 메소텔린에 결합하는 인간 항체 및 이의 용도
GB0720552D0 (en) * 2007-10-19 2007-11-28 Iti Scotland Ltd Multiple cluster knockout
AU2008323206B2 (en) 2007-11-12 2014-08-14 U3 Pharma Gmbh AXL antibodies
EP2344536A1 (de) 2008-09-19 2011-07-20 MedImmune, LLC Gegen dll4 gerichtete antikörper und anwendungen davon
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
JP6053517B2 (ja) 2009-05-05 2016-12-27 ノヴィミュンヌ エスア 抗ｉｌ−１７ｆ抗体およびそれらの使用法
CN105999263B (zh) 2009-11-13 2021-06-29 第一三共欧洲有限公司 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
EP2502993B1 (de) * 2009-11-17 2017-07-26 Sanford Applied Biosciences L.L.C. Hac-vektor (human artificial chromosome - künstliches menschliches chromosom)
BR122021025338B1 (pt) 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
CN103619881B (zh) 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
AU2012332587B2 (en) 2011-11-01 2017-02-23 Bionomics, Inc. Antibodies and methods of treating cancer
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
PE20141937A1 (es) 2011-11-16 2014-12-18 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
PL2812443T3 (pl) 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
CN104271122A (zh) 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
JP6133544B2 (ja) * 2012-03-16 2017-05-24 康宏 香月 ミクロセル保存方法
RS57414B1 (sr) 2012-03-16 2018-09-28 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
BR112014022855A2 (pt) 2012-03-16 2017-07-18 Regeneron Pharma animal não humano geneticamente modificado, mamífero geneticamente modificado, e, método para fabricar um animal não humano
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
CN103387955B (zh) * 2012-05-10 2015-04-29 上海南方模式生物科技发展有限公司 非人哺乳动物b淋巴细胞缺陷动物模型的制备方法及其用途
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
ES2944477T3 (es) 2013-02-06 2023-06-21 Inhibrx Inc Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos
EP2970446A1 (de) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antikörperkonstrukte für influenza m2 und cd3
HUE045859T2 (hu) 2013-03-15 2020-01-28 Amgen Res Munich Gmbh N-terminális ABP-t tartalmazó, egyláncú kötõmolekulák
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
CA2916259C (en) 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
CA2921398C (en) 2013-08-14 2021-12-14 The Governing Council Of The University Of Toronto Antibodies for inhibiting frizzled receptors and pharmaceutical compositions containing antibodies for inhibiting frizzled receptors
EP3049442A4 (de) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6721502B2 (ja) 2014-05-02 2020-07-15 株式会社カイオム・バイオサイエンス ヒト抗体を産生する細胞
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
AU2015295242B2 (en) 2014-07-31 2020-10-22 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh Constructos de anticuerpos para cdh19 y cd3
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
PT3283524T (pt) 2015-04-17 2023-06-05 Amgen Res Munich Gmbh Construções de anticorpos biespecíficos para cdh3 e cd3
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
KR20180101623A (ko) 2016-02-03 2018-09-12 암젠 리서치 (뮌헨) 게엠베하 Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MA43955B1 (fr) 2016-02-03 2022-02-28 Amgen Inc Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
KR102413037B1 (ko) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
WO2017161414A1 (en) 2016-03-22 2017-09-28 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
AU2017348743C1 (en) * 2016-10-31 2022-03-03 National University Corporation Tottori University Human antibody–producing non-human animal and method for preparing human antibodies using same
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
SG11201909547TA (en) 2017-05-05 2019-11-28 Amgen Inc Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
WO2018233608A1 (en) * 2017-06-19 2018-12-27 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED TO CD28 HUMAN OR CHIMERIC
CN109136261B (zh) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化cd28基因改造动物模型的制备方法及应用
EP3652211A1 (de) 2017-07-14 2020-05-20 Pfizer Inc. Antikörper gegen madcam
CN109837307B (zh) * 2017-11-24 2023-09-19 中国科学院脑科学与智能技术卓越创新中心 建立含外源染色体的胚胎干细胞的方法
BR112020011627A2 (pt) 2017-12-11 2020-11-17 Amgen Inc. processo de fabricação contínuo para produtos de anticorpos biespecíficos
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
US20210301017A1 (en) 2018-07-30 2021-09-30 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
AU2019314999A1 (en) 2018-08-03 2021-02-11 Amgen Inc. Antibody constructs for CLDN18.2 and CD3
BR112021003436A2 (pt) 2018-08-27 2021-05-18 Affimed Gmbh células nk criopreservadas pré-carregadas com uma construção de anticorpo
SG11202103275YA (en) 2018-10-11 2021-04-29 Amgen Inc Downstream processing of bispecific antibody constructs
CN112400022B (zh) 2019-02-18 2023-06-30 百奥赛图(北京)医药科技股份有限公司 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物
US20220259547A1 (en) 2019-06-13 2022-08-18 Amgeng Inc. Automated biomass-based perfusion control in the manufacturing of biologics
US20220281966A1 (en) 2019-07-26 2022-09-08 Amgen Inc. Anti-il13 antigen binding proteins
EP4028416A1 (de) 2019-09-10 2022-07-20 Amgen Inc. Reinigungsverfahren für bispezifische antigen-bindende polypeptide mit erhöhter dynamischer bindungskapazität beim protein-l-einfang
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
CA3164129A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
EP4093771A1 (de) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Kombinationen von antikörperkonstrukten und inhibitoren des zytokinfreisetzungssyndroms und verwendungen davon
EP4118113A1 (de) 2020-03-12 2023-01-18 Amgen Inc. Verfahren zur behandlung und prophylaxe von crs bei patienten mit einer kombination aus bispezifischen antikörpern zur bindung an cds x-krebszellen und tnfalpha- oder il-6-hemmer
WO2021188851A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs
US20230365709A1 (en) 2020-10-08 2023-11-16 Affimed Gmbh Trispecific binders
CA3199976A1 (en) 2020-11-06 2022-05-12 Amgen Research (Munich) Gmbh Polypeptide constructs selectively binding to cldn6 and cd3
WO2022096698A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Polypeptide constructs binding to cd3
TW202233678A (zh) 2020-11-06 2022-09-01 德商安美基研究（慕尼黑）公司 具有增強的剪切特徵的多肽
IL302599A (en) 2020-11-06 2023-07-01 Amgen Inc Bispecific molecules bind multi-target antigens of increased selectivity
AR125290A1 (es) 2021-04-02 2023-07-05 Amgen Inc Construcciones de unión a mageb2
WO2022234102A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
EP4376958A1 (de) 2021-07-30 2024-06-05 Affimed GmbH Duplexkörper
TW202334221A (zh) 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
WO2023090361A1 (ja) 2021-11-16 2023-05-25 国立大学法人鳥取大学 改変ｄ領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA874410B (en) * 1986-06-24 1988-04-27 Merrell Dow Pharma Fusion products

Also Published As

Publication number Publication date
DE69636868D1 (de) 2007-03-15
WO1997007671A1 (fr) 1997-03-06
EP1916300A1 (de) 2008-04-30
CN101333516A (zh) 2008-12-31
AU6837696A (en) 1997-03-19
CA2230759A1 (en) 1997-03-06
CN1200014A (zh) 1998-11-25
EP0773288A2 (de) 1997-05-14
TW448032B (en) 2001-08-01
HK1008472A1 (en) 1999-11-12
JP4318736B2 (ja) 2009-08-26
AU718138B2 (en) 2000-04-06
EP0843961A1 (de) 1998-05-27
KR19990044300A (ko) 1999-06-25
EP0843961A4 (de) 2000-08-09
EP0773288A3 (de) 1997-07-09
ATE352613T1 (de) 2007-02-15
JP2008200042A (ja) 2008-09-04
DE69636868T2 (de) 2007-10-25
EP0843961B1 (de) 2007-01-24
CN100379857C (zh) 2008-04-09
KR100308764B1 (ko) 2001-12-17
CA2230759C (en) 2012-02-21

Similar Documents

Publication Publication Date Title
DK0843961T3 (da) Kimærisk mus og fremgangsmåde til at producere samme
DK0972445T3 (da) Kimærisk mus som udtrykker et humant antistof
AU1595195A (en) Embryonic stem cells as nuclear donors and nuclear transfer techniques to produce chimeric and transgenic animals
ES2121803T3 (es) Plantas de zea mays y plantas transgenicas de zea mays generadas a partir de protoplastos o celulas derivadas de protoplastos.
ATE415812T1 (de) Stress-gekoppelte kalium kanal proteine sowie methoden zu deren verwendung in pflanzen
FI950277A0 (fi) Ksenogeenisten vasta-aineiden tuotanto
NZ336612A (en) Cloning using donor nuclei from proliferating somatic cells
WO2000031237A3 (en) Method of cloning porcine animals
DE3580654D1 (de) Menschlicher hybridomfusionspartner zur herstellung menschlicher monoklonaler antikoerper.
DK448988A (da) Praeparat af et alfa-amideringsenzym og fremgangsmaade til fremstilling og anvendelse deraf
DK1085083T3 (da) Dyrkningsmedium for dyreceller og fremgangsmåde til proteinfremstilling under anvendelse af dette
FI880383A (fi) Transformation och expression av en fraemmande gen i brassicaarter.
TR200000099T1 (tr) Üzüm için yenilenme sistemi ve kullanımı.
TW367365B (en) An improved method for obtaining plant somatic embryos about the somatic embryo suspension cultures and pro-embryogenic mass suspension cultures
ATE330003T1 (de) Rekombinanter stabiler zellklon, seine herstellung und verwendung
DK0453458T3 (da) Fremgangsmåde til fremstilling af et transgent ikke-menneskeligt dyr ved indføring af exogent DNA i somatiske dyreceller og germdyreceller
GB2369828A (en) Nuclear transfer with selected donor cells
DK0658626T3 (da) Fremgangsmåder til produktion af protein C
WO2000068371A8 (fr) Procede de culture cellulaire
DE60208173D1 (de) Produktion von genetisch geänderten pflanzen mit püroindoline
CA2284133A1 (en) Novel cell line and screening method with the use of the same
UA11267A (uk) Спосіб підбору оптимальhого строку культивуваhhя клітиh еhдокриhhих оргаhів, призhачеhих для траhсплаhтації